The initiative, with the support of MoHFW, will directly impact a population of more than 5.7 million that depend on the public health value chain across the 10 districts
As of FY21, it is the largest independent medical device company and the second-largest company overall, in the surgical consumables market in India with a 7.91 per cent share based on the value
CRISIL Ratings has revised its outlook on the long term ratings of Krishna Institute Of Medical Sciences Limited (KIMS) to 'Positive' from 'Stable' while reaffirming the ratings at 'CRISIL AA-/CRISIL A1+'
Winlevi, the recently added anti-acne product with a new mechanism of action and broad-based use (vs Absorica), will further boost the derma portfolio and Speciality business growth
The company has an outlay of Rs 120-140 crore as R & D expense for FY 22
Turnover of API division of ISLL stood at Rs 856.58 crore
The company posted net profit of Rs.111.44 crores for the period ended June 30, 2020.
The company recorded revenue of Rs 528crore as compared to Rs 444 crore, registering a growth of 19% over the corresponding quarter ended 31st March 2020
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
India formulations business grew 14.7% YoY with recovery in industry growth from COVID-19 impact
Subscribe To Our Newsletter & Stay Updated
